INFLUENCE OF SOMATIC COMORBIDITY ON THE COURSE OF CORONARY HEART DISEASE

Aim. To assess the life quality and clinical-laboratory parameters of the stable coronary heart disease (CHD) patients comorbid with diabetes type 2 (DM) and chronic obstructive pulmonary disease (COPD).

Material and methods. Totally, 67 patients included, age 39-69 y.o. All patients were selected to 3 groups: CHD (group 1, n=21, mean age 55,4±6,8 y.o., males/ females 16/5), CHD and DM (group 2, n=21, 58,8±8,9 y.o., M/F 18/6), and CHD and COPD (group 3, n=22, 59,2±5,2 y.o., M/F 16/6). Clinical and anamnestic, as biochemical and hemodynamic parameters were evaluated, and the life quality with EQ-5D score.

Results. In the CHD group with or none DM there was high rate of obesity, but in COPD group mean body mass index was lower than 29 kg/m2 . By EQ-5D, life quality decrease in CHD and DM, at most was determined by the units as “dyscomfort”, “everyday activities” and “anxiety/depression”. In CHD patients with comorbid COPD maximum was collected in the points related to “mobility”, “anxiety/ depression”. In the absence of significant dilation of the left ventricle (LV), in the patients of groups 2 and 3 there were relatively low values of ejection fraction (EF) comparing to CHD only patients. Also, in COPD and CHD patients there were signs of the left atrium overload, as the Doppler digns of pulmonary hypertension. Comorbidity of CHD and DM was followed by increased plasma urea and more significant dyslipidemia.

Conclusion. Comorbid DM and COPD contribute on the worsening of CHD patients parameters with following decline in life quality, increased plasma urea and more significant dyslipidemia.

1. Boytsov SA, Chuchalin AG. Prophylaxis of chronic non-infectious diseases.Recommendation.2013; 6-7. (Бойцов С.А., Чучалин А.Г. Профилактика хронических неинфекционных заболеваний. Рекомендации.2013;6-7.http://www.zdrav-novgorod.ru/np-includes/upload/2014/03/12/4378.pdf)

2. Global atlas on cardiovascular disease prevention and control with them. Ed.: Mendis S, Puska P, Norrving B. World Health Organization, Geneva, 2013; 6-7.

3. Oganov RG. Vascular comorbidity: a common approach to prevention and treatment. Rational Pharmacotherapy in Cardiology. 2015: 11 (1); 4-7. Russian (Оганов Р.Г. Сосудистая коморбидность: общие подходы к профилактике и лечению. Рациональная фармакотерапия в кардиологии. 2015: 11(1); 4-7)

4. Demographic Yearbook of Russia 2014. Moscow: Rosstat; 2015. Russian (Демографический ежегодник России 2014.Москва: Росстат; 2015)

5. IDF Diabetes Atlas. Sixth edition, 2014 update. Online version of IDF Diabetes Atlas. Available from: http://www.idf.org/diabetesatlas

6. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006 Jan 14; 332(7533):73-8.

7. Man SF, Leipsic JA, Man JP, Sin DD. Is atherosclerotic heart disease in COPD a distinct phenotype? Chest 2011; 140 (3): 569-71.

8. Zhang J, Rutten FH, Cramer MJ, et al. The importance of cardiovascular disease for mortality in patients with COPD: a prognostic cohort study. Fam Pract 2011; 28 (5): 474-81.

9. Tolpygina SN, Martsevich SY, Deev AD. The influence of concomitant diseases on a long-term prognosis in patients with chronic ischemic heart disease according to the PROGNOZ IBS register.Ration Pharmacother Cardiol 2015; 11(6):571-576. Russian (Толпыгина С.Н., Марцевич С.Ю., Деев А.Д. Влияние сопутствующих заболеваний на отдаленный прогноз пациентов с хронической ишемической болезнью сердца по данным регистра «ПРОГНОЗ ИБС».Рациональная фармакотерапия в кардиологии 2015;11(6):571-576)

10. Zhang M., Holman C. D., Price S. D. et al. Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study // BMJ. 2009; 338: a2752.

11. Amirjanova VN, Erdes S. Validation of the Russian version of the general questionnaire EuroQol 5D (EQ-5D).Scientific and practical rheumatology. 2007; 3: 69-75. Russian (Амирджанова В.Н., Эрдес Ш.Валидация русской версии общего опросника EuroQol 5D (EQ-5D). Научно-практическая ревматология. 2007; 3: 69–75)

12. Ferrières J, Rouyer MV, Lautsch D, et al. Dyslipidemia International Study (DYSIS) II France Study Group. Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study. Arch Cardiovasc Dis. 2017 Mar; 110(3):167-178.

13. Rodríguez Padial L, Maicas Bellido C, Alcalá López J, et al. Limited application of prevention measures in patients with diabetes mellitus type 2 and coronary artery disease in Spain. DIETRIC study. Rev Clin Esp. 2005 Jan; 205(1):14-8.

14. Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. Thorax. 2016; 71(6):493-50

15. Stamler J, Neaton JD, Cohen JD, et al. MRFIT Research Group. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc. 2012 Oct; 1(5)